

AMENDMENT TO THE CLAIMS

Claims 51 and 52 are amended and Claims 85-90 are added herein. The following replaces all prior versions and listings of the claims.

Listing of the claims:

Claims 1-50 (Cancelled)

Claim 51. (Currently Amended) An isolated cardiomyocyte cell, including comprising an introduced nucleic acid molecule, wherein said molecule encodes a polypeptide having the amino acid sequence of SEQ. I.D. NO. 2, and wherein said cardiomyocyte cell exhibits enhanced proliferative potential relative a control cardiomyocyte cell that does not comprise the introduced nucleic acid molecule.

Claim 52. (Currently Amended) An isolated cardiomyocyte cell, including comprising an introduced nucleic acid molecule, wherein said molecule encodes a polypeptide having the amino acid sequence of SEQ. I.D. NO. 4, and wherein said cardiomyocyte cell exhibits enhanced proliferative potential relative a control cardiomyocyte cell that does not comprise the introduced nucleic acid molecule.

Claims 63-84 (Cancelled).

Claim 85. (New) A screening method for obtaining information on the activity of an agent, comprising contacting a cardiomyocyte cell according to claim 51 with the agent and obtaining therefrom information on the activity of the agent.

Claim 86. (New) The screening method of claim 85, wherein the cardiomyocyte cell is mammalian.

Claim 87. (New) The Screening method of claim 85, wherein the cardiomyocyte cell is human.

Claim 88. (New) A screening method for obtaining information on the activity of an agent, comprising contacting a cardiomyocyte cell according to claim 52 with the agent and obtaining therefrom information on the activity of the agent.

Claim 89. (New) The screening method of claim 88, wherein the cardiomyocyte cell is mammalian.

Claim 90. (New) The Screening method of claim 90, wherein the cardiomyocyte cell is human.